Oragenics (NYSE:OGEN) Earns Sell Rating From Analysts at StockNews.com
Oragenics (NYSE:OGEN) Earns Sell Rating From Analysts at StockNews.com
StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Get Rating) in a report issued on Monday morning. The firm issued a sell rating on the stock.
Oragenics Stock Performance
Shares of NYSE OGEN opened at $3.31 on Monday. The stock has a market cap of $6.49 million, a PE ratio of -0.43 and a beta of 0.37. Oragenics has a 12-month low of $2.61 and a 12-month high of $24.00.
Get Oragenics alerts:Oragenics Company Profile
(Get Rating)
Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.
Further Reading
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- ASML Reports Massive Growth, Management Points To Sluggish 2023
- Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
- Mullen Automotive: Is The Bloom Off The Rose?
- Diversified Abbott Laboratories Could Reverse And Move Higher
- Okta Reversal In Progress While Catalysts Approach
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Get Rating) in a report issued on Monday morning. The firm issued a sell rating on the stock.
StockNews.com 开始报道的股票 Oragenics（纽约证券交易所代码：OGEN — 获取评级） 在周一上午发布的一份报告中。该公司对该股发布了卖出评级。
Oragenics Stock Performance
Oragenics 股票表现
Shares of NYSE OGEN opened at $3.31 on Monday. The stock has a market cap of $6.49 million, a PE ratio of -0.43 and a beta of 0.37. Oragenics has a 12-month low of $2.61 and a 12-month high of $24.00.
纽约证券交易所OGEN的股票周一开盘价为3.31美元。该股票的市值为649万美元，市盈率为-0.43，beta值为0.37。Oragenics的12个月低点为2.61美元，为12个月高点24.00美元。
Oragenics Company Profile
Oragenics 公司简介
(Get Rating)
（获取评级）
Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.
Oragenics Inc是一家生物技术公司，专注于开发和许可用于改善人类健康的创新产品和技术。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- ASML Reports Massive Growth, Management Points To Sluggish 2023
- Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
- Mullen Automotive: Is The Bloom Off The Rose?
- Diversified Abbott Laboratories Could Reverse And Move Higher
- Okta Reversal In Progress While Catalysts Approach
- 免费获取 StockNews.com 关于 Oragenics (OGEN) 的研究报告
- ASML报告了大规模增长，管理层指出2023年表现疲软
- 分析师 Boost 会让洛克希德·马丁公司的股价上涨、上涨和下跌吗？
- Mullen Automotive：是玫瑰花的吗？
- 多元化的雅培实验室可能会逆转并走高
- 催化剂接近时Okta的逆转正在进行中
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Oragenics Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Oragenics及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧